Literature DB >> 11562627

Interferon-beta treatment in patients with childhood-onset multiple sclerosis.

Y Mikaeloff1, T Moreau, M Debouverie, J Pelletier, C Lebrun, O Gout, J M Pedespan, C Van Hulle, P Vermersch, G Ponsot.   

Abstract

We present a report of the use of interferon-beta before 18 years of age in 16 patients with childhood-onset multiple sclerosis. This study demonstrated that the treatment is safe and well tolerated.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11562627     DOI： 10.1067/mpd.2001.117004

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  34 in total

Review 1.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 2.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

Review 3.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

4.  Pediatric multiple sclerosis.

Authors:  Yashma Patel; Vikram Bhise; Lauren Krupp
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 5.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 6.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

7.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

8.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 9.  Pediatric multiple sclerosis.

Authors:  Brenda L Banwell
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

10.  Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

Authors:  Angelo Ghezzi; Maria Pia Amato; Pietro Annovazzi; Marco Capobianco; Paolo Gallo; Loredana La Mantia; Maria Giovanna Marrosu; Vittorio Martinelli; Nicoletta Milani; Lucia Moiola; Francesco Patti; Carlo Pozzilli; Maria Trojano; Mauro Zaffaroni; Giancarlo Comi
Journal:  Neurol Sci       Date:  2009-04-22       Impact factor: 3.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.